Skip to main content
SpringerLink
Log in
Book cover

Microcirculation pp 237–251Cite as

Management of No-Reflow

  • Chapter
  • First Online:

  • 593 Accesses

Abstract

Despite considerable progress in percutaneous coronary interventions, the phenomenon of coronary no-reflow (NR) still represents a serious problem. It occurs when cardiac tissue fails to perfuse normally despite opening of the occluded vessel. The consequences of NR include infarct expansion, early congestive heart failure, ventricular arrhythmias and adverse left ventricular remodeling. All the actions that improve myocardial tissue perfusion should convert into a better prognosis and a better clinical outcome. The pathophysiology of NR is still not fully elucidated, and several mechanisms are proposed, with microvascular obstruction as the leading one. Despite considerable progress in the identification of the risks to NR development, no specific therapies have been developed so far. In this review, pharmacological and nonpharmacological interventions that might improve coronary blood flow are discussed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54(6):1496–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Management of no-reflow phenomenon in the catheterization laboratory. JACC Cardiovasc Interv. 2017;10(3):215–23.

    Article  PubMed  Google Scholar 

  3. Berry C, Maznyczka AM, McCartney P. Failed myocardial reperfusion during primary PCI: an unmet therapeutic need. EuroIntervention. 2019;14(16):1628–30.

    Article  PubMed  Google Scholar 

  4. Carrick D, Haig C, Ahmed N, et al. Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. Circ Cardiovasc Imaging. 2016;9(1):e004148.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: state of the art. Arch Cardiovasc Dis. 2015;108:661–74.

    Article  PubMed  Google Scholar 

  6. Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol. 2010;23(5):429–36.

    Article  PubMed  Google Scholar 

  7. Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion following by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57–65.

    Article  CAS  PubMed  Google Scholar 

  8. Di Carli NF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol. 2003;41(8):1387–93.

    Article  PubMed  CAS  Google Scholar 

  9. Li XD, Yang YJ, Hao YC, et al. Effects of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis. Chin Med J. 2013;126(9):1755–60.

    PubMed  Google Scholar 

  10. Pantsios C, Kapelios C, Vakrou S, et al. Effect of elevated reperfusion pressure on “no reflow” area and infarct size in a porcine model of ischemia-reperfusion. J Cardiovasc Pharmacol Ther. 2016;21(4):405–11.

    Article  PubMed  Google Scholar 

  11. Ipek G, Onuk T, Karatas MB, et al. CHA2DS2-VASc score is a predictor of no-reflow in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous intervention. Angiology. 2016;67(9):840–5.

    Article  PubMed  Google Scholar 

  12. Kurtul A, Murat SN, Yarliogluez M, et al. Mild to moderate renal impairment is associated with no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. Angiology. 2015;66(7):644–51.

    Article  PubMed  Google Scholar 

  13. Kurtul A, Yarlioglues M, Celik IE, et al. Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis. 2015;26(8):706–12.

    Article  PubMed  Google Scholar 

  14. Amano H, Ikeda T, Toda M, et al. Plaque composition and no-reflow phenomenon during percutaneous coronary intervention of low-echoic structures in grayscale intravascular ultrasound. Int Heart J. 2016;57(3):285–91.

    Article  CAS  PubMed  Google Scholar 

  15. Suda A, Namiuchi S, Kawaguchi T, et al. A simple and rapid method for identification of lesions at high risk for the no-reflow phenomenon immediately before elective coronary stent implantation. Heart Vessel. 2016;31(12):1904–14.

    Article  Google Scholar 

  16. Grygier M, Araszkiewicz A, Lesiak M, Grajek S. Role of adenosine as an adjunct therapy in the prevention and treatment of no-reflow phenomenon in acute myocardial infarction with ST segment elevation: review of the current data. Kardiol Pol. 2013;71(2):115–20.

    Article  PubMed  Google Scholar 

  17. Fischell TA, Maheshewari A. Current applications for nicardipine in invasive and interventional cardiology. J Invasive Cardiol. 2004;16(8):428–32.

    PubMed  Google Scholar 

  18. Wang HJ, Lo PH, Lin JJ, et al. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv. 2004;63(2):171–6.

    Article  PubMed  Google Scholar 

  19. Johnson-Cox HA, Yang D, Ravid K. Physiological implications of adenosine receptor-mediated platelet aggregation. J Cell Physiol. 2011;226(1):46–51.

    Article  CAS  Google Scholar 

  20. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of adenosine(AMISTAD) trial. J Am Coll Cardiol. 1999;34(6):1711–20.

    Article  CAS  PubMed  Google Scholar 

  21. Ross AM, Gibbons RJ, Stone GW, AMISTAD-II Investigators, et al. A randomized, double-blinded, placebo controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45(11):1775–80.

    Article  CAS  PubMed  Google Scholar 

  22. Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006;92(9):1278–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Niccoli G, Rigattieri S, De Vita MR, et al. Open label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the intervention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013;6(6):580–9.

    Article  PubMed  Google Scholar 

  24. Navarese EP, Buffon A, Andreotti F, et al. Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. Atherosclerosis. 2012;222(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  25. Gao Q, Yang B, Guo Y, Zheng F. Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2015;94(32):e1279.

    Article  CAS  Google Scholar 

  26. Su Q, Nyi TS, Li L. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev. 2015;5:CD009503.

    Google Scholar 

  27. Polimeni A, De Rosa S, Sabatino J, et al. Impact of intracoronary adenosine administration during primary PCI: a meta-analysis. Int J Cardiol. 2016;203:1032–41.

    Article  PubMed  Google Scholar 

  28. Bulluck H, Sirker A, Loke YK, et al. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials. Int J Cardiol. 2016;202:228–37.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Nazir SA, McCann GP, Greenwood JP. Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial. Eur Heart J. 2016;37:1910–9.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Yetgin T, Uitterdijk A, te Lintel HM, et al. Limitation of infarct size and no-reflow by intracoronary adenosine depends critically on dose and duration. JACC Cardiovasc Interv. 2015;8(15):1990–9.

    Article  PubMed  Google Scholar 

  31. Su Q, Li L, Liu Y. Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Cardiol. 2013;36(8):E11–6.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft intervention: comparison of intracoronary verapamil and nitroglycerin. Catheter Cardiovasc Diagn. 1996;39(2):113–8.

    Article  CAS  Google Scholar 

  33. Wang L, Cheng Z, Gu Y, Peng D. Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. Biomed Res Int. 2015;2015:382086.

    PubMed  PubMed Central  Google Scholar 

  34. Fischell TA, Haller S, Pulukurthy S, Virk IS. Nicardipine and adenosine “flush cocktail” to prevent no-reflow during rotational atherectomy. Cardiovasc Revasc Med. 2008;9(4):224–8.

    Article  PubMed  Google Scholar 

  35. Fischell TA, Subraya RG, Ashraf K, et al. “Pharmacologic” distal protection sing prophylactic, intragraft nicardipine to prevent no-reflow and non-Q wave myocardial infarction during elective saphenous vein graft intervention. J Invasive Cardiol. 2007;19(2):58–62.

    PubMed  Google Scholar 

  36. Lambert CR, Pepine CJ. Effects of intravenous and intracoronary nicardipine. Am J Cardiol. 1989;64(15):8H–15H.

    Article  CAS  PubMed  Google Scholar 

  37. Ferrari R. The role of mitochondria in ischemic heart disease. J Cardiovasc Pharmacol. 1996;28:1–10.

    Google Scholar 

  38. Wu M, Huang Z, Xie H, Zhou Z. Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. PLoS One. 2013;8(10):e78231.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Parham WA, Bouhasin A, Ciaramita JP, et al. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation. 2004;109(10):1236–43.

    Article  CAS  PubMed  Google Scholar 

  40. Kobatake R, Sato T, Fujiwara Y, et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessel. 2011;26(4):379–84.

    Article  Google Scholar 

  41. Parikh KH, Chag MC, Shah KJ, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol. 2007;85(3–4):476–82.

    Article  CAS  PubMed  Google Scholar 

  42. Su Q, Li L, Naing KA, Sun Y. Safety and effectiveness of nitroprusside in preventing no-reflow during percutaneous coronary intervention: a systematic review. Cell Biochem Biophys. 2014;68(1):201–6.

    Article  CAS  PubMed  Google Scholar 

  43. Zhao S, Qi G, Tian W, et al. Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention: a meta-analysis. J Interv Cardiol. 2014;27(4):356–64.

    Article  PubMed  Google Scholar 

  44. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J. 2006;152(5):887.

    Article  PubMed  CAS  Google Scholar 

  45. Poupko JM, Baskin SI, Moore E. The pharmacological properties of anisodamine. J Appl Toxicol. 2007;27(2):116–21.

    Article  CAS  PubMed  Google Scholar 

  46. Niu X, Zhang J, Bai M, et al. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. BMC Cardiovasc Disord. 2018;18(1):3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Ibanez B, James S, Agewall S, ESC Scientific Document Group, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.

    Article  PubMed  Google Scholar 

  48. Roffi M, Patrono C, Collet JP, ESC Scientific Document Group, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.

    Article  CAS  PubMed  Google Scholar 

  49. Thiele H, Wöhrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet. 2012;379(9819):923–31.

    Article  CAS  PubMed  Google Scholar 

  50. Kirma C, Erkol A, Pala S, et al. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012;79(1):59–67.

    Article  PubMed  Google Scholar 

  51. Sun B, Liu Z, Yin H, et al. Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(40):e8223.

    Article  CAS  Google Scholar 

  52. Potdar A, Sharma S. The ‘MAP strategy’ (maximum aspiration of atherothrombus and adjunctive glycoprotein IIb/IIIa inhibitor utilization combined with prolonged inflation of balloon/stent) for preventing no-reflow in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a retrospective analysis of seventy-one cases. Indian Heart J. 2015;67(Suppl 3):S43–6.

    Article  PubMed  Google Scholar 

  53. Chen WR, Tian F, Chen YD, et al. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. Int J Cardiol. 2016;208:109–14.

    Article  PubMed  Google Scholar 

  54. Agarwal SK, Agarwal S. Role of intracoronary fibrinolytic therapy in contemporary PCI practice. Cardiovasc Revasc Med. 2018. https://doi.org/10.1016/j.carrev.2018.11.021.

  55. Sezer M, Oflaz H, Gören T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J. 2007;356(18):1823–34.

    Article  CAS  Google Scholar 

  56. Sezer M, Çimen A, Aslanger E, et al. Effect of intracoronary streptokinase administered immediately after primary percutaneous coronary intervention on long-term left ventricular infarct size, volumes, and function. J Am Coll Cardiol. 2009;54(12):1065–71.

    Article  CAS  PubMed  Google Scholar 

  57. Geng W, Zhang Q, Liu J, et al. A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST segment elevation myocardial infarction. J Interv Cardiol. 2018;31(2):136–43.

    Article  PubMed  Google Scholar 

  58. Sun B, Liu J, Yin H, et al. Delayed vs. immediate stenting in STEMI with a high thrombus burden: a systematic review and meta-analysis. Herz. 2018. https://doi.org/10.1007/s00059-018-4699-x.

  59. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation. 2005;112(14):2143–8.

    Article  PubMed  Google Scholar 

  60. Grube E, Schofer JJ, Webb J, et al. Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts. Am J Cardiol. 2002;89(8):941–5.

    Article  PubMed  Google Scholar 

  61. Grube E, Gerckens U, Yeung AC, et al. Prevention of distal embolisation during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation. 2001;104(20):2436–41.

    Article  CAS  PubMed  Google Scholar 

  62. Gick M, Jander N, Bestehorn HP, et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without st-segment elevation. Circulation. 2005;112(10):1462–9.

    Article  PubMed  Google Scholar 

  63. Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123–30.

    Article  CAS  PubMed  Google Scholar 

  64. De Vita M, Burzotta F, Biondi-Zoccai GG, et al. Individual patient-data meta-analysis comparing clinical outcome in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention with or without prior thrombectomy. ATTEMPT study: a pooled Analysis of Trials on ThrombEctomy in acute Myocardial infarction based on individual PatienT data. Vasc Health Risk Manag. 2009;5(1):243–7.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Mongeon FP, Bélisle P, Joseph L, et al. Adjunctive thrombectomy for acute myocardial infarction: a bayesian meta-analysis. Circ Cardiovasc Interv. 2010;3(1):6–16.

    Article  PubMed  Google Scholar 

  66. Awadalla H, Salloum J, Moustapha A, et al. Rheolytic thrombectomy does not prevent slow-, no-reflow during percutaneous coronary intervention in acute myocardial infarction. Int J Angiol. 2003;12(3):183–7.

    Article  Google Scholar 

  67. Jolly SS, James S, Džavík V, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation. 2017;135(2):143–52.

    Article  PubMed  Google Scholar 

  68. Herring MJ, Dai W, Hale SL, Kloner RA. Rapid induction of hypothermia by the ThermoSuit system profoundly reduces infarct size and anatomic zone of no reflow following ischemia-reperfusion in rabbit and rat hearts. J Cardiovasc Pharmacol Ther. 2015;20(2):193–202.

    Article  PubMed  Google Scholar 

  69. Noc M, Erlinge D, Neskovic AN. COOL AMI EU pilot trial: a multicentre, prospective, randomised controlled trial to assess cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction. EuroIntervention. 2017;13(5):e531–9.

    Article  PubMed  Google Scholar 

  70. Mewton N, Thibault H, Roubille F, et al. Postconditioning attenuates no-reflow in STEMI patients. Basic Res Cardiol. 2013;108(6):383.

    Article  PubMed  Google Scholar 

  71. Ovize M, Baxter GF, Di Lisa F, Working Group of Cellular Biology of Heart of European Society of Cardiology, et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2010;87(3):406–23.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia

    Danijela Trifunovic

  2. Faculty of Medicine, Belgrade University, Belgrade, Serbia

    Danijela Trifunovic, Jelena Dudic & Natalija Gavrilovic

  3. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

    Olivia Manfrini

Authors
  1. Danijela Trifunovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jelena Dudic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalija Gavrilovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olivia Manfrini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiology, Carol Davila University of Medicine, Bucharest, Romania

    Maria Dorobantu

  2. Cardiovascular Program-ICCC, IR- Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

    Lina Badimon

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Trifunovic, D., Dudic, J., Gavrilovic, N., Manfrini, O. (2020). Management of No-Reflow. In: Dorobantu, M., Badimon, L. (eds) Microcirculation. Springer, Cham. https://doi.org/10.1007/978-3-030-28199-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28199-1_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28198-4

  • Online ISBN: 978-3-030-28199-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation